Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an ...

Clinical data also showed that seven out of 10 patients treated with Rybelsus met a blood sugar (HbA1c) target of 7% or less, compared with the UK average of 40%. Novo added that the drug also ...

It's currently dominated by a few big names in Eli Lilly and Novo Nordisk, but that can change drastically in the future. The ...

Existing obesity drugs like Wegovy and Eli Lilly's Zepbound are injectable. Pills require larger amounts of active ...

Half a century of advancements in biomedical science paved the way for today's powerful weight-loss drugs like Ozempic -- so ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

In a recent study published in the New England Journal of Medicine, researchers found that Novo Nordisk's drug liraglutide ... consequences are in 30 years or 40 years,'" he said.

Novo Nordisk already sells an older, once-daily injectable drug for obesity – Saxenda (liraglutide ... latest results call that it has round 40% payer coverage in the US so far for Wegovy ...

Pills require larger amounts of active ingredients ... U.S., but have shed 15% since peaking in June this year. Around 40% of Novo's valuation is pinned to its pipeline of experimental drugs ...

Pills require larger amounts of active ingredients ... but have shed 15% since peaking in June this year. Around 40% of Novo's valuation is pinned to its pipeline of experimental drugs, analysts ...